Design, synthesis and biological evaluation of some 2-azetidinone derivatives as potential antihyperlipidemic agents

Archiv der Pharmazie

Volumn 346, Issue 12, 2013, Pages 872-881

  Arya, Nikhilesh ^a,b   Dwivedi, Jaya ^b   Khedkar, Vijay M ^c   Coutinho, Evans C ^c   Jain, Kishor S ^a  

^a Sinhgad Institute of Pharmaceutical Sciences   (India)

^b BANASTHALI UNIVERSITY   (India)

^c BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

2 Azetidinone; Antihyperlipidemic; Ezetimibe; Molecular docking; NPC1L1

Indexed keywords

2 AZETIDINONE DERIVATIVE; 4 CHLORO N [3 CHLORO 4 (4 HYDROXYPHENYL) 2 OXOAZETIDIN 1 YL]BENZAMIDE; 4 CHLORO N [4 (4 HYDROXYPHENYL) 2 OXO 3 PHENYLAZETIDIN 1 YL]BENZAMIDE; ANTILIPEMIC AGENT; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; N [3 CHLORO 4 (4 HYDROXYPHENYL) 2 OXOAZETIDIN 1 YL]BENZAMIDE; N [3 CHLORO 4 (4 HYDROXYPHENYL) 2 OXOAZETIDIN 1 YL]ISONICOTINAMIDE; N [3 CHLORO 4 (4 HYDROXYPHENYL) 2 OXOAZETIDIN 1 YL]NICOTINAMIDE; N [4 (4 HYDROXYPHENYL) 2 OXO 3 PHENYLAZETIDIN 1 YL]BENZAMIDE; N [4 (4 HYDROXYPHENYL) 2 OXO 3 PHENYLAZETIDIN 1 YL]ISONICOTINAMIDE; N [4 (4 HYDROXYPHENYL) 2 OXO 3 PHENYLAZETIDIN 1 YL]NICOTINAMIDE; NIEMANN PICK C1 LIKE 1 PROTEIN; PROTEIN; TRIACYLGLYCEROL; TYLOXAPOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERLIPIDEMIC ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL MODEL; FEMALE; HYPERLIPIDEMIA; INFRARED SPECTROSCOPY; LIPOPROTEIN BLOOD LEVEL; MALE; MASS SPECTROMETRY; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

2-AZETIDINONE; ANTIHYPERLIPIDEMIC; EZETIMIBE; MOLECULAR DOCKING; NPC1L1;

ANIMALS; AZETIDINES; BINDING SITES; BIOLOGICAL MARKERS; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; DRUG DESIGN; FEMALE; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; POLYETHYLENE GLYCOLS; PROTEIN CONFORMATION; RATS; RATS, WISTAR;

EID: 84889669427     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201300262     Document Type: Article

References (43)

1. a) K. S. Jain, R. R. Kulkarni, D. P. Jain, Mini-Rev. Med. Chem. 2010, 10, 232-262
2. b) H. C. McGill, Jr., Geographical Pathology of Atheroslclerosis, Williams and Wilken Co, Baltimore 1985
3. c) M. L. Overturf, D. S. Loose-Mitchell, Curr. Opin. Lipidol. 1992, 3, 179-185
4. d) A. Ghatak, O. Asthana, Indian J. Pharmacol. 1995, 27, 14-29
5. e) P. Schwandt, Klin. Wochenschr 1990, 68, 54-58.
6. a) http://www.americanheart.org/statistics. (American Heart Association: 2001 Heart and Stroke Statistical Update.Dallas Texas: American Heart Association 2000)
7. b) K. S. Jain, M. K. Kathiravan, R. S. Somani, C. J. Shishoo, Bioorg. Med. Chem. 2007, 15, 4674-4699.
8. a) P. D. Mehta, N. P. S. Sengar, A. K. Phathak, Eur. J. Med. Chem. 2010, 45, 5541-5560
9. b) G. S. Singh, Mini-Rev. Med. Chem. 2004, 4 (69), 93
10. c) M. Toraskar, V. Kulkarni, V. Kadam, J. Pharm. Res. 2010, 3, 169-173
11. d) V. Wable, A. Pathak, T. Patil, Med. Chem. 2012, 4, 15.
12. a) J. A. Pfefferkorn, S. D. Larsen, C. V. Huis, R. Sorenson, T. Barton, T. Winters, B. Auerbach, C. Wu, T. J. Wolfram, H. Cai, K. Welch, N. Esmaiel, J. Davis, R. Bousley, K. Olsen, S. B. Mueller, T. Mertz, Bioorg. Med. Chem. Lett. 2008, 18, 546-553
13. b) X. Xianxiu, F. Renzhong, C. Jin, C. Shengwu, B. Xu, Bioorg. Med. Chem. Lett. 2007, 17, 101-104
14. c) Y. Wang, H. W. Huang, H. Zhang, J. Zhou, Lett. Drug Des. Discov. 2011, 8, 500
15. d) N. Arya, M. K. Munde, J. Dwivedi, A. Y. Jagdale, K. S. Jain, Arch. Pharm. Chem. Life Sci. 2013, 346, 588-595.
16. a) http://www.dailyfinance.com/2013/05/03/fda-approves-mercks-Hpt (FDA approves Merck's LIPTRUZET™ (ezetimibe and atorvastatin), a new product that can help powerfully lower LDL cholesterol. In a clinical study, LIPTRUZET™ powerfully lowered LDL-C across all doses on average by more than 50%-63% in a dosage range of 10/10 mg/day through 10/80 mg/day.)
17. b) M. K. Kathiravan, M. K. Munde, D. P. Jain, K. S. Jain, Indian Drugs 2009, 46, 91-103
18. c) www.indstate.edu/theme/mwking/lipid. (This home page belongs to Indiana state university and Carnegie foundation built for the advancement of teaching, Michael, W; King, Ph.D./IU School of Medicine).
19. a) L. Ge, J. Wang, W. Qi, H. H. Miao, J. Cao, Y. X. Qu, B. L. Li, B. L. Song, Cell Metabol. 2008, 7, 508-519
20. b) A. B. Weinglass, M. Kohler, U. Schulte, J. Liu, E. O. Nketiah, A. Thomas, W. Schmalhofer, B. Williams, W. Bildl, D. R. McMasters, K. Dai, L. Beers, M. E. McCann, G. J. Kaczorowski, M. L. Garcia, PNAS 2008, 105, 11140-11145
21. c) M. G. Calvo, J. M. Lisnock, H. G. Bull, B. E. Hawes, D. A. Burnett, M. P. Braun, J. H. Crona, H. R. Davis, Jr., D. C. Dean, P. A. Detmers, M. P. Graziano, M. Hughes, D. E. MacIntyre, A. Ogawa, K. A. O'Neill, S. P. N. Iyer, D. E. Shevell, M. M. Smith, Y. S. Tang, A. M. Makarewicz, F. Ujjainwalla, S. W. Altmann, K. T. Chapman, N. A. Thornberry, PNAS 2005, 102, 8132-8137.
22. E. T. Bodor, S. Offermanns, Br. J. Pharmacol. 2008, 153, S68-S75.
23. a) P. Zhan, X. Liu, Curr. Pharm. Des. 2009, 15, 1893-1917
24. b) D. A. Brooks, G. J. Etgen, C. J. Rito, A. J. Shuker, S. J. Dominianni, A. M. Warshawsky, R. Ardecky, J. R. Paterniti, J. Tyhonas, D. S. Karanewsky, R. F. Kauffman, C. L. Broderick, B. A. Oldham, C. R. Montrose, L. L. Winneroski, M. M. Faul, J. R. McCarthy, J. Med. Chem. 2001, 44, 2061-2064
25. c) V. Cecchetti, A. Fravolini, F. Schiaffella, O. Tabarrini, G. Bruni, G. Segre, J. Med. Chem. 1993, 36, 157-161.
26. a) http://www.rcsb.org/pdb/explore/explore.do?structureId=3QNT
27. b) H. J. Kwon, M. Palnitkar, J. Deisenhofer, Plos One 2011, 6, 1-7.
28. a) G. S. Singh, T. Pheko, Indian J. Chem. 2008, 47B, 159-162
29. b) A. K. Sharma, S. N. Mazumdar, M. P. Mahajan, J. Org. Chem. 1996, 61, 5506-5509
30. c) O. M. Dragostin, F. Lupascu, C. Vasile, M. Mares, V. Nastasa, R. F. Moraru, D. Pieptu, L. Profire, Molecules 2013, 18, 4140-4157.
31. a) J. S Prasad, L. S Liebeskind, Tetrahedron Lett. 1988, 29, 4253-4256
32. b) C. Palomo, A. Arrieta, F. P. Cossio, J. M. Aizpurna, A. Mielgo, N. Aurrekoetxea, Tetrahedron Lett. 1990, 31, 6429-6432
33. c) W. Lwowsky, in Comprehensive Heterocyclic Chemistry, Vol. 7 (Eds.:, A. R. Katritzky, C. W. Rees,) Pergamon Press, Oxford 1984, Chapter 5.01
34. d) M. Browne, D. A. Burnett, M. A. Caplen, L. Y. Chen, J. W. Clader, M. Domalski, S. Dugar, P. Pushpavanam, R. Sher, W. Vaccaro, M. Viziano, H. Zhao, Tetrahedron Lett. 1995, 36, 2555-2558
35. e) J. Xu, ARKIVOC 2009, 9, 21-24
36. f) W. T. Braddy, Y. Q. Gu, J. Org. Chem. 1989, 54, 2834-2838
37. g) L. S. Hegedus, J. Montgomery, Y Narukawa, D. C. Snustad, J. Am. Chem. Soc. 1991, 113, 5784-5791.
38. Y. Wang, H. Zhang, W. Huang, J. Kong, J. Zhou, B. Zhang, Eur. J. Med. Chem. 2009, 44, 1638-1643.
39. M. C. Chrysselis, E. A. Rekka, P. N. Kourounakis, J. Med. Chem. 2000, 43, 609-612.
40. A. B. Thomas, O. Paradkar, R. K. Nanda, P. N. Tupe, P. A. Sharma, R. Badhe, L. Kothapalli, A. Banerjee, S. Hamane, A. Deshpande, Green Chem. Lett. Rev. 2010, 3, 293-300.
41. A. A. Rajput, S. S. Rajput, Int. J. Pharm. Res. 2009, 1, 1605-1611.
42. R. Patel, A. Mangal, G. Engla, S. Bhadoriya, J. Pharm. Res. 2012, 5, 2159-2161.
43. N. Ramalakshmi, R. Vijayakumar, K. Ilango, S. Arunkumar, A. Puratchikody, Int. J. Chem. Sci. 2008, 6, 1213-1222.